Nicolas Morgan, Partner, DLA Piper to Speak at KC’s Event on Revenue Recognition for Biotech Firms on 7/29/2009
New York, NY, June 23, 2009 --(PR.com)-- The Knowledge Congress, the leading producer of regulatory focused webcast announced today that Nicolas Morgan, Partner, DLA Piper, will speak at the Knowledge Congress’ upcoming webcast entitled: “Revenue Recognition for Biotech Firms Live Webcast”. This 2-hour event is scheduled on July 29, 2009, Wednesday at 3:00 PM – 5:00 PM ET. (For further details of the event and an updated list of panelists, please visit: http://knowledgecongress.org/event_2009_Biotech.html)
Event Summary
Biotechnology companies face considerable challenges in applying accounting principles related to revenue recognition because they partner with larger companies through collaborative arrangements to pursue scientific innovation. Under these arrangements, the companies agree to share technology and research costs associated with bringing medical therapies to market and this gives them access to additional funding and commercialization networks. How the companies should recognize revenues under these arrangements is not entirely clear under current accounting guidance, and some companies have had to restate their financial results because of the lack of clarity. Moreover, some commentators have suggested that the current rules may not accurately reflect the underlying economics of the deals.
The Knowledge Congress is assembling a panel of accounting and biotechnology industry experts to help biotechnology company finance and legal advisers understand the revenue recognition principals as applied in this industry. Panel members will share their expertise in a Live two-hour Webcast.
About Nicholas Morgan
Nick Morgan practices complex securities litigation in state and federal courts with special emphasis in representing issuers, officers and directors, investment funds, analysts, and brokers in connection with Securities and Exchange Commission and Financial Industry Regulatory Authority investigations, litigation, and arbitration. Mr. Morgan also advises clients in non-litigation settings, such as counseling public companies, funds and broker-dealer firms in securities compliance and corporate governance issues, conducting internal investigations and assisting in regulatory examinations by the SEC's Division of Corporation Finance and Office of Compliance Inspections and Examinations.
For more than seven years, from 1998 to 2005, Mr. Morgan prosecuted securities fraud in the SEC’s Enforcement Division, rising from staff attorney to branch chief to senior trial counsel. Additionally, Mr. Morgan served as a Special Assistant US Attorney for the Southern District of California, obtaining indictments against the principals of a $330 million subprime mortgage lending scheme.
While at the SEC, Mr. Morgan was lead counsel on a wide variety of litigated matters including prosecution of insider trading, investment adviser fraud, revenue recognition fraud, broker/dealer fraud, mutual fund market timing, and market manipulation. He was also lead trial counsel in a multi-week jury trial in the Southern District of California in which he obtained verdicts against the former CEO and CFO of a publicly traded company for violation of the antifraud provisions of the federal securities laws.
Mr. Morgan writes and speaks on SEC enforcement and securities litigation issues and has served as a faculty member, speaker, and panelist at conferences on corporate compliance and securities regulation.
About The Knowledge Congress
The Knowledge Congress is an organization that produces webcast that examine regulatory changes across a variety of industries. “We bring together the world's leading authorities and industry participants through informative two-hour Live webcast to study the impact of changing regulations.”
To contact or to register for an event, please visit: www.knowledgecongress.org.
###
Event Summary
Biotechnology companies face considerable challenges in applying accounting principles related to revenue recognition because they partner with larger companies through collaborative arrangements to pursue scientific innovation. Under these arrangements, the companies agree to share technology and research costs associated with bringing medical therapies to market and this gives them access to additional funding and commercialization networks. How the companies should recognize revenues under these arrangements is not entirely clear under current accounting guidance, and some companies have had to restate their financial results because of the lack of clarity. Moreover, some commentators have suggested that the current rules may not accurately reflect the underlying economics of the deals.
The Knowledge Congress is assembling a panel of accounting and biotechnology industry experts to help biotechnology company finance and legal advisers understand the revenue recognition principals as applied in this industry. Panel members will share their expertise in a Live two-hour Webcast.
About Nicholas Morgan
Nick Morgan practices complex securities litigation in state and federal courts with special emphasis in representing issuers, officers and directors, investment funds, analysts, and brokers in connection with Securities and Exchange Commission and Financial Industry Regulatory Authority investigations, litigation, and arbitration. Mr. Morgan also advises clients in non-litigation settings, such as counseling public companies, funds and broker-dealer firms in securities compliance and corporate governance issues, conducting internal investigations and assisting in regulatory examinations by the SEC's Division of Corporation Finance and Office of Compliance Inspections and Examinations.
For more than seven years, from 1998 to 2005, Mr. Morgan prosecuted securities fraud in the SEC’s Enforcement Division, rising from staff attorney to branch chief to senior trial counsel. Additionally, Mr. Morgan served as a Special Assistant US Attorney for the Southern District of California, obtaining indictments against the principals of a $330 million subprime mortgage lending scheme.
While at the SEC, Mr. Morgan was lead counsel on a wide variety of litigated matters including prosecution of insider trading, investment adviser fraud, revenue recognition fraud, broker/dealer fraud, mutual fund market timing, and market manipulation. He was also lead trial counsel in a multi-week jury trial in the Southern District of California in which he obtained verdicts against the former CEO and CFO of a publicly traded company for violation of the antifraud provisions of the federal securities laws.
Mr. Morgan writes and speaks on SEC enforcement and securities litigation issues and has served as a faculty member, speaker, and panelist at conferences on corporate compliance and securities regulation.
About The Knowledge Congress
The Knowledge Congress is an organization that produces webcast that examine regulatory changes across a variety of industries. “We bring together the world's leading authorities and industry participants through informative two-hour Live webcast to study the impact of changing regulations.”
To contact or to register for an event, please visit: www.knowledgecongress.org.
###
Contact
The Knowledge Group, LLC/The Knowledge Congress Live Webcast Series
Thomas LaPointe, Jr., Executive Director
1.800.578.4370
www.knowledgecongress.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
1.800.578.4370
www.knowledgecongress.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories